Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KZR |
---|---|---|
09:32 ET | 1406 | 0.579 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kezar Life Sciences Inc | 41.5M | -0.4x | --- |
LAVA Therapeutics NV | 49.7M | -1.8x | --- |
DURECT Corp | 42.2M | -1.6x | --- |
Atara Biotherapeutics Inc | 36.9M | -0.1x | --- |
Evogene Ltd | 33.9M | -1.4x | --- |
Correlate Energy Corp | 26.1M | -1.7x | --- |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.5M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.28 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.